Search
Search titles only
By:
Search titles only
By:
Menu
Forums
New posts
Search forums
Home
What's new
New posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Reply to thread
Home
Heath
Alternative Medicine
Psychedelics as novel therapeutics in Alzheimer's disease.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
[QUOTE="greenmedinfo, post: 3090"] PMID: Curr Top Behav Neurosci. 2021 Nov 4. Epub 2021 Nov 4. PMID: 34734390 Abstract Title: Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. Abstract: Serotonin 2A receptor (5-HTR) agonist "classic psychedelics" are drawing increasing interest as potential mental health treatments. Recent work suggests psychedelics can exert persisting anxiolytic and antidepressant effects lasting up to several months after a single administration. Data indicate acute subjective drug effects as important psychological factors involved in observed therapeutic benefits. Additionally, animal models have shown an important role for 5-HTR agonists in modulating learning and memory function with relevance for Alzheimer's Disease (AD) and related dementias. A number of biological mechanisms of action are under investigation to elucidate 5-HTR agonists' therapeutic potential, including enhanced neuroplasticity, anti-inflammatory effects, and alterations in brain functional connectivity. These diverse lines of research are reviewed here along with a discussion of AD pathophysiology and neuropsychiatric symptoms to highlight classic psychedelics as potential novel pharmacotherapies for patients with AD. Human clinical research suggests a possible role for high-dose psychedelic administration in symptomatic treatment of depressed mood and anxiety in early-stage AD. Preclinical data indicate a potential for low- or high-dose psychedelic treatment regimens to slow or reverse brain atrophy, enhance cognitive function, and slow progression of AD. In conclusion, rationale and potential approaches for preliminary research with psychedelics in patients with AD are presented, and ramifications of this line of investigation for development of novel AD treatments are discussed. [URL='https://www.greenmedinfo.com/article/psychedelics-novel-therapeutics-alzheimers-disease']read more[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Home
Heath
Alternative Medicine
Psychedelics as novel therapeutics in Alzheimer's disease.
Top
Bottom
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
